The Fly

Bristol-Myers’ Sotyktu recommended for approval in psoriasis by Europe’s CHMP

Bristol Myers announced that the Committee for Medicinal Products for Human Use – CHMP – of the European Medicines Agency has recommended the approval of Sotyktu for the treatment of adults with moderate-to-severe plaque psoriasis. The CHMP recommendation will now be reviewed by the European Commission, which has the authority to approve medicines for the European Union – EU -. The CHMP adopted this positive opinion based on results from the pivotal Phase 3 POETYK PSO-1 and POETYK PSO-2 trials. Sotyktu demonstrated significant and clinically meaningful improvements in skin clearance, symptom burden and quality of life measures compared to placebo and Otezla. Sotyktu was well-tolerated with a low rate of discontinuation due to adverse events. The FDA approved Sotyktu for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy in September 2022, and Japan’s Ministry of Health, Labour and Welfare approved Sotyktu for the treatment of adults with plaque psoriasis, generalized pustular psoriasis, and erythrodermic psoriasis who have had an inadequate response to conventional therapies in September 2022. In addition to the European Medicines Agency, Sotyktu is also under regulatory review by other health authorities around the world for the treatment of moderate-to-severe plaque psoriasis.

Published first on TheFly

See today’s best-performing stocks on TipRanks >>

Read More on BMY:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More